Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
We have previously reported on phase I/II studies of irinotecan plus S-1 therapy for advanced gastric cancer. Based on the safety and efficacy data that were obtained, this phase II study was planned to assess the efficacy of irinotecan plus S-1 for patients with advanced colorectral cancer. A total of 40 patients are enrolled at 13 medical institutions. The objective of this study was to establish a useful chemotherapy regimen for an out-patient setting.
Komatsu
Yoshito
Y
Department of Gastroenterology, Hokkaido University School of Medicine, North 15, West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan. ykomatsu@med.hokudai.ac.jp.
Yuuki
Satoshi
S
Fuse
Nozomu
N
Takei
Masaaki
M
Kato
Takashi
T
Miyagishima
Takuto
T
Kudo
Mineo
M
Kunieda
Yasuyuki
Y
Tateyama
Miki
M
Wakahama
Osamu
O
Meguro
Takashi
T
Ohizumi
Hiroko
H
Watanabe
Maso
M
Akita
Hirotoshi
H
Sakata
Yu
Y
Asaka
Masahiro
M
D000230:Adenocarcinoma / Q000188:drug therapy*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin